Trial Profile
A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone-Sensitive Metastatic Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Bicalutamide; Goserelin; Leuprorelin; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 15 Feb 2020 Results analysing Survival outcomes and risk group validation in patients treated with androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer, presented at the 2020 Genitourinary Cancers Symposium
- 23 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Results assessing plasma miRNAs as potential biomarkers of response (n=50) published in the Prostate